Nanobiotix (NASDAQ: NBTX) joins Euronext Tech Leaders Index

Rhea-AI Filing Summary

Nanobiotix S.A. filed a Form 6-K to share that it has been included in the Euronext Tech Leaders segment and added to the Euronext Tech Leaders Index. This Euronext initiative highlights innovative, high-growth European technology companies and aims to increase their visibility with international investors.

The company describes itself as a late-stage clinical biotechnology business pioneering physics-based nanotherapeutic approaches for cancer and other major diseases. Headquartered in Paris and listed on Euronext Paris and the Nasdaq Global Select Market, Nanobiotix owns more than 30 umbrella patents across three nanotechnology platforms in oncology, bioavailability and biodistribution, and central nervous system disorders.

Key Figures

Year incorporated: 2003 Euronext Paris listing since: 2012 Nasdaq listing since: December 2020 +3 more

6 metrics

Year incorporated 2003 Company incorporation year

Euronext Paris listing since 2012 Year Nanobiotix listed on Euronext Paris

Nasdaq listing since December 2020 Nasdaq Global Select Market listing

Umbrella patents More than 30 Patents associated with three nanotechnology platforms

Nanotechnology platforms 3 platforms Oncology, bioavailability and biodistribution, CNS disorders

Form month June 2026 Form 6-K reporting month for index inclusion

Key Terms

Euronext Tech Leaders Index, Euronext Tech Leaders segment, late-clinical stage biotechnology company, nanotherapeutic, +2 more

6 terms

Euronext Tech Leaders Index financial

"Nanobiotix Joins the Euronext Tech Leaders Index"

Euronext Tech Leaders segment financial

"its inclusion in the Euronext Tech Leaders segment and Euronext Tech Leaders Index"

late-clinical stage biotechnology company technical

"the Company, a late-clinical stage biotechnology company pioneering nanotherapeutic approaches"

nanotherapeutic technical

"pioneering nanotherapeutic approaches to expand treatment possibilities"

A nanotherapeutic is a medical treatment that uses tiny engineered particles—think microscopic delivery trucks—to carry drugs or therapeutic agents directly to specific cells or tissues. Investors track these therapies because they can improve effectiveness and reduce side effects compared with traditional drugs, but they also bring higher development, manufacturing and regulatory risks that can significantly affect a company’s clinical success, costs and future revenue potential.

forward-looking statements regulatory

"This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

universal registration document regulatory

"Nanobiotix’s 2025 universal registration document filed with the AMF on March 31, 2026"

A universal registration document is a single, comprehensive filing that collects a publicly traded company's key disclosures — such as business description, financial statements, risk factors, governance and legal information — into one place for regulators and investors. Think of it as a detailed owner’s manual and scorecard combined: it saves time when the company issues new shares or bonds and helps investors compare, check risks, and make informed decisions without hunting through many separate reports.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-39777

Nanobiotix S.A.
(Translation of registrant's name into English)

60 Rue de Wattignies 75012 Paris, France
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

On June 2, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated June 2, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Nanobiotix S.A.
		(Registrant)
Date: June 2, 2026		/s/ Bart Van Rhijn
		Bart Van Rhijn
		Chief Financial Officer

EXHIBIT 99.1

Nanobiotix Joins the Euronext Tech Leaders Index

PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced its inclusion in the Euronext Tech Leaders segment and Euronext Tech Leaders Index, a Euronext flagship initiative dedicated to increasing the visibility and attractiveness of Europe’s leading and high-growth technology companies among international investors.

“Nanobiotix was founded on the belief that applying physics to medicine could unlock entirely new therapeutic possibilities,” said Laurent Levy, chief executive officer of Nanobiotix and chairman of the executive board. “Our inclusion in the Euronext Tech Leaders segment recognizes not only the progress we have made as a company, but also the broader potential of physics-based innovation to contribute meaningfully to the future of healthcare. We are honored to join this community of European innovators and look forward to continuing our mission of building new therapies designed to improve outcomes for millions of patients around the world.”

Launched by Euronext in 2022, the Euronext Tech Leaders initiative brings together a select group of companies recognized for their innovation, growth profile, and contribution to the European technology ecosystem. Members benefit from increased visibility among international investors, access to a broad network of market participants, and participation in a range of events and initiatives designed to support long-term growth.

For Nanobiotix, inclusion in the Euronext Tech Leaders segment reflects the Company’s position at the intersection of nanotechnology, physics, and medicine, as it advances a portfolio of physics-based nanotherapeutic platforms designed to address significant unmet medical needs.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Disclaimer

This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company’ management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on March 31, 2026 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2025 universal registration document filed with the AMF on March 31, 2026 under “chapter 1.5 Risk Factors”, and subsequent filings Nanobiotix makes with the SEC and AMF from time to time, which are available on the SEC’s website at www.sec.gov and on the AMF's website at www.amf.org, The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 joanne.choi@nanobiotix.com Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr	Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com

Attachment

• 2026-06-02 -- NBTX -- Joins Euronext Tech Leaders Index -- FINAL (https://ml.globenewswire.com/Resource/Download/30cd04f8-8490-44e0-9d0f-c7c4b06455dd)

FAQ

What did Nanobiotix (NBTX) announce in its June 2026 Form 6-K?

Nanobiotix announced its inclusion in the Euronext Tech Leaders segment and Euronext Tech Leaders Index. This Euronext initiative recognizes innovative, high-growth European technology companies and is designed to increase their visibility and attractiveness among international investors.

What is the Euronext Tech Leaders Index and segment for Nanobiotix (NBTX)?

The Euronext Tech Leaders segment and Index group selected companies recognized for innovation, growth profile, and contribution to the European technology ecosystem. Members like Nanobiotix benefit from increased investor visibility, a broad market network, and events aimed at supporting long-term growth.

How does Nanobiotix (NBTX) describe its core business focus?

Nanobiotix describes itself as a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches. Its work focuses on nanotherapeutic platforms designed to improve treatment outcomes in oncology, bioavailability and biodistribution, and central nervous system disorders for millions of patients.

Where is Nanobiotix (NBTX) headquartered and where are its shares listed?

Nanobiotix is headquartered in Paris, France. Its shares have been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020, reflecting a dual listing in Europe and the United States.

What intellectual property does Nanobiotix (NBTX) report in this filing?

Nanobiotix reports owning more than 30 umbrella patents associated with three nanotechnology platforms. These platforms cover applications in oncology, bioavailability and biodistribution, and central nervous system disorders, supporting its strategy around physics-based nanotherapeutic innovations.

What forward-looking statement caution does Nanobiotix (NBTX) include?

Nanobiotix cautions that its press release contains forward-looking statements based on current expectations and assumptions. It notes that various known and unknown risks and uncertainties could cause actual results to differ materially from these statements, and references its risk factor disclosures in regulatory filings.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 7.8 KB